Benitec licenses technology to French transgenic rat firm
Tuesday, 22 March, 2005
Benitec (ASX:BLT) has granted a worldwide, non-exclusive commercial licence to French company genOway to develop transgenic rodents with Benitec's proprietary DNA-directed RNA-inferference technology (ddRNAi).
Under the agreement, genOway will be free to provide customers with advanced in vivo RNAi technologies to facilitate drug discovery and development, from target validation through to safety studies.
Benitec announced today that GenOway will pay Benitec an up-front licence fee and pay ongoing royalties, but it did not disclose details of the agreement.
GenOway is widely regarded in Europe as a leader in creating advanced mouse and rat models for basic research and drug discovery, Benitec said. The company holds IP rights to multiple knockout and knock-in processes for developing animal models. It also offers a range of solutions for both gene expression and inactivation in rodent modes.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
